Microorganism strain CRC2631 of Salmonella typhimurium and its use as a cancer therapeutic

#The Sequence Listing, which is a part of the present disclosure, includes a text file “CRC_ST25.txt,” generated by U.S. Patent & Trademark Office Patent In Version 3.5 software, comprising nucleotide sequences of the present invention. This .txt file has been filed electronically herewith and is incorporated herein by reference in its entirety.

#1. Field of the Invention

#The present invention relates generally to a novel microorganism strain, Salmonella typhimurium CRC2631, and it use as a cancer therapeutic.

#FIG. 1: Fluorescent CRC2636 binds preferentially to PC-3M cells but not to normal RWPE-1 cells.

#FIG. 2: CRC2631 more effectively invades PC-3M carcinoma cells over time.

#FIG. 3: Archived S. typhimurium preferentially targets PC-3M prostate carcinoma cells but do not target normal RWPE-1 prostate cells.

#“Agent” or “Therapeutic Agent:” As used herein, the terms “agent” and “therapeutic agent” refer to any natural or synthesized composition that when administered to a subject relieves the subject of disease or improves health. Wherein the disease being treated is cancer. The “agent” or “therapeutic agent” may be a pro-drug, further defined below.

#“Bind, Binds, or Interacts With:” As used herein, “bind,” “binds,” or “interacts with” means that one molecule recognizes and adheres to a particular second molecule in a sample, in vitro or in vivo, but does not substantially recognize or adhere to other structurally-unrelated molecules in the sample. Generally, a first molecule that “specifically binds” a second molecule has a binding affinity of greater than about 105 or 106 moles/liter for that second molecule.

#“Gene:” As used herein, the term “gene” means a nucleic acid molecule that codes for a particular protein, or in certain cases, a functional or structural RNA molecule.